+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Chronic Plaque Psoriasis - Pipeline Insight, 2020

  • PDF Icon

    Clinical Trials

  • 106 Pages
  • February 2020
  • Region: Global
  • DelveInsight
  • ID: 4745373
Chronic Plaque Psoriasis - Pipeline Insight, 2020 report outlays comprehensive insights of present scenario and growth prospects across Chronic Plaque Psoriasis. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type.

Products covered by Phase
  • Phase III, Phase II, Phase I
  • Pre-clinical & Discovery
  • Inactive (Discontinued and Dormant)

Overview of pipeline development activities for Chronic Plaque Psoriasis

Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.

Therapeutic segmentation of products for Chronic Plaque Psoriasis

The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this indication.


Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts.

Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
  • Provides an overview of therapeutic pipeline activity for Chronic Plaque Psoriasis across the complete product development cycle including all clinical and non-clinical stages
  • It comprises of detailed profiles of Chronic Plaque Psoriasis therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
  • Coverage of dormant and discontinued pipeline projects across Chronic Plaque Psoriasis

Reasons to Buy
  • Establish a comprehensive understanding of the current pipeline scenario across Chronic Plaque Psoriasis to formulate effective R&D strategies
  • Assess challenges and opportunities that influence Chronic Plaque Psoriasis R&D
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify the relationship between the product and use it for target finding, drug repurposing, and precision medicine
  • Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Chronic Plaque Psoriasis to enhance and expand business potential and scope
  • Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs

Table of Contents

1. Report Introduction2. Chronic Plaque Psoriasis - Disease Overview
3. Pipeline Outlook
  • An Overview of Pipeline Products for Chronic Plaque Psoriasis

4. Comparative Analysis
5. Chronic Plaque Psoriasis Therapeutic Products in Clinical Stage
5.1 Drug Name : Company Name
  • Product Description
  • Research and Development
  • Product Development Activities

6. Chronic Plaque Psoriasis Therapeutic Products in Non-clinical Stage
6.1 Drug Name : Company Name
  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Pipeline Analysis
  • Pipeline Analysis by Route of Administration
  • Pipeline Analysis by Stage and Route of Administration
  • Pipeline Analysis by Molecule Type
  • Pipeline Analysis by Stage and Molecule Type

8. Inactive Pipeline Products
8.1 Drug Description
  • Research and Development Studies
  • Product Development Activities
  • Reason for dormancy/discontinuation

AppendixReport MethodologyConsulting ServicesDisclaimerAbout the Publisher
Certain sections of the table of contents would vary according to the availability of information

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Novartis Pharmaceuticals
  • Mayssen Research & Development
  • UCB Biopharma
  • Pfizer
  • Cellceutix Corporation
  • AbbVie
  • Kadmon Corporation
  • UCB Biopharma
  • Biogen
  • AbGenomics
  • Glenmark Farmacêutica Ltda
  • ApoPharma
  • ASIS Corporation
  • Elorac Inc.